Elixiron Immunotherapeutics (Cayman) Limited
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Elixiron Immunotherapeutics is a clinical-stage biotechnology company listed on the Taipei Emerging Stock Board (7871.TWO), developing differentiated immune-modulating therapies.
The company is advancing two Phase II programs in the US and Taiwan following favorable Phase I safety results.
Indemakitug (EI-001) is a fully human anti-IFN-γ monoclonal antibody in Phase II for vitiligo targeting the IFN-γ axis, a central pathogenic driver of the disease. The program represents a differentiated precision immunology approach distinct from JAK inhibition strategies, with top-line data anticipated in H1 2027.
Enrupatinib (EI-1071) is a brain-penetrant CSF-1R inhibitor in Phase II for Alzheimer’s disease targeting microglial-driven neuroinflammation, with top-line data anticipated in late 2026.
The Alzheimer’s program has received two Part the Cloud awards from the Alzheimer’s Association (US$1.8M), and Elixiron has raised ~US$70M to date.
Company HQ City:
Grand Cayman
Company HQ State:
Cayman Islands
Company HQ Country:
Cayman Islands
Year Founded:
2017
Lead Product in Development:
(1) EI-001 (anti-IFN-γ monoclonal antibody) for vitiligo; (2) EI-1071 (brain-penetrant CSF-1R inhibitor) for Alzheimer’s disease
CEO
Dr. Hung-Kai Chen
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
Exchange
TPEx
Ticker
7871.TWO
When you expect your next catalyst update?
Late 2026
What is your next catalyst (value inflection) update?
Top-line Phase II clinical results for EI-1071, a brain-penetrant CSF-1R inhibitor targeting microglial-driven neuroinflammation in Alzheimer’s disease.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}